Trial Profile
Study of sunitinib and/or pazopanib in patients with advanced clear-cell renal-cell carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2016
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 29 Mar 2016 New trial record